2Miglino M,Santini G,Grasso R,et al.Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation[J].Haematologica,2001,86(7):706-714.
3Czuczman,A.J.Grillo-Lopez,C.A.White,et al.Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy[J].Clin Oncol,1999,17(1):268-276.
5Plosker GL,Figgitt DP.Rituximab:a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia[J].Drugs.2003,63(8):803-843.
6Kosits C,Callaghan M.Rituximab:a new monoclonal antibody therapy for non-Hodgkin's lymphoma[J].Oncol Nurs Forum,2000,27(1):51-59.
7Coiffier B,Altman A,Pui CH,et al.Guidelines for the management of pediatric and adult tumor lysis syndrome:an evidence-based review[J].J Clin Oncol,2008,26(16):2767-2778.
9O'Connor OA, Portlock C, Moskowitz C, et al. Time to treatment response in patients with follicular tymphoma trea- ted with bortezomib is longer compared other histologic sub- types[J]. Clin Cancer Res,2010,16:719-726.
10Baiocchi RA, Alinari L, Lustberg ME,et al. Phase 2 trial of rituximab and hortezomih in patients with relapsed or refracto- ry mantle cell and follicular lymphoma[J]. Cancer, 2010,117: 2442-2451.
